AstraZeneca shares fall 5% on disappointing lung cancer drug trial results

AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results.

The Covid-19 vaccine maker was trading at the bottom of the FTSE 100 and dragged the wider healthcare sector lower after data published Monday showed that its experimental drug did not significantly improve overall survival results for patients.

Share were down 4.9% by 9:43 a.m. London time.

This is a breaking news story. Please check back for updates.

Source

World

Yen extends gains after Takaichi election victory, U.S. data in focus

February 10, 2026

The dollar nursed losses on Tuesday ahead of monthly economic data, while the yen held on to its gains after Prime Minister Sanae Takaichi’s election victory. Irina Marwan | Moment | Getty Images The U.S. dollar extended Monday’s decline against the yen after Prime Minister Sanae Takaichi’s election victory, while remaining little changed against European […]

World

UBS downgrades U.S. IT sector despite a recovery. It gave 3 reasons why

February 10, 2026

Key Points UBS downgraded its outlook on U.S. IT stocks on Tuesday, citing lingering “software uncertainty” and increased capital expenditure. The Swiss investment bank’s move comes after a sell-off in software stocks over the past week as investors turn cautious towards the sector. UBS recommended investors diversify exposure to other sectors, including healthcare and utilities. […]

World

Gold ticks lower on increased risk appetite; investors await U.S. economic data

February 10, 2026

Gold fell on Tuesday as investors stayed cautious ahead of U.S. jobs and inflation data that would indicate the Federal Reserve’s interest rate trajectory. Oliver Strewe | The Image Bank | Getty Images Gold prices eased on Tuesday, as improved risk appetite lifted global equities, while investors awaited a series of U.S. economic data later this week […]